Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Ruixue LiuState Key Laboratory of Respiratory Health and Multimorbidity National Center of Technology Innovation For Animal Model Key Laboratory of Pathogen Infection Prevention and Control (Peking Union Medical College) Ministry of Education Institute of Laboratory Animal Science Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Xintian ZhangInstitute of Medical Biology Chinese Academy of Medical Sciences & Peking Union Medical College Kunming China.
Longying ShenState Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Cong TangInstitute of Medical Biology Chinese Academy of Medical Sciences & Peking Union Medical College Kunming China.
Junbin WangInstitute of Medical Biology Chinese Academy of Medical Sciences & Peking Union Medical College Kunming China.
Yu ChengState Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Wenhai YuInstitute of Medical Biology Chinese Academy of Medical Sciences & Peking Union Medical College Kunming China.
Bin YinDepartment of Molecular Biology and Biochemistry Institute of Basic Medical Sciences Medical Primate Research Center Neuroscience Center Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Xiandao PanState Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Xiaozhong PengInstitute of Medical Biology Chinese Academy of Medical Sciences & Peking Union Medical College Kunming China.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The ongoing evolution of SARS-CoV-2 and its immune-evading variants underscores an urgent requirement for broad-spectrum antiviral drugs. In this study, a series of lycorine derivatives was synthesized. This led to the identification of compound
Indexed as
–1 programmed ribosomal frameshiftingantiviral agentlycorine derivativesSARS‐CoV‐2zinc‐finger antiviral protein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lycorine Derivative Inhibits SARS-CoV-2 Replication by Reducing -1 Programmed Ribosomal Frameshifting via Targeting ZAP. · full record | OpenQuestion